VORINOSTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H20N2O3
Molecular Weight	264.3207
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CCCC(=NO)O)CCC(=Nc1ccccc1)O

InChI

InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N

InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

HIDE SMILES / InChI

Molecular Formula	C14H20N2O3
Molecular Weight	264.3207
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB02546
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Plasmodium falciparum 3D7 5 Target ID: CHEMBL2366922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26199860	Inhibitor 7728	0.12 µM [IC50]
NCI-H661 1 Target ID: CHEMBL1075544 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722	Inhibitor 7728	0.13 µM [IC50]
Histone deacetylase 1 49 Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722	Inhibitor 7728	0.15 µM [IC50]
Histone deacetylase 2 35 Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722	Inhibitor 7728	0.28 µM [IC50]
Histone deacetylase 8 17 Target ID: CHEMBL3192 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722	Inhibitor 7728	1.68 µM [IC50]
Histone deacetylase 3 34 Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19410459	Inhibitor 7728	57.0 nM [IC50]
Histone deacetylase 6 26 Target ID: CHEMBL1865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25734520	Inhibitor 7728	1.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cutaneous T-cell lymphoma 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	Primary		Approved 8043	Zolinza Approved Use Treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Launch Date 1.16000634E12

C_max

Value	Dose	Analyte	Population
1.2 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	VORINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT
0.83 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:
1.17 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:

AUC

Value	Dose	Analyte	Population
5.5 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	VORINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT
4.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:
5.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:

T_1/2

Value	Dose	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	VORINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT
1.94 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:
2.3 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472	400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered:	VORINOSTAT plasma	Homo sapiens population: unhealthy age: sex: food status:

F_unbound

Value	Dose	Co-administered	Analyte	Population
29% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		VORINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT

Doses

Dose	Population	Adverse events
250 mg 2 times / day multiple, oral Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18297527	unhealthy, 63 years (range: 38 - 74 years) n = 5 Health Status: unhealthy Condition: advanced multiple myeloma Age Group: 63 years (range: 38 - 74 years) Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/18297527	DLT: Fatigue... Dose limiting toxicities: Fatigue (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18297527
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021991lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16960145	unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021991lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16960145	Disc. AE: Thrombocytopenia, Anemia... Other AEs: Hypotension, Sepsis... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 3-4, 8%) Anemia (grade 3-4, 17%) Deep vein thrombosis (grade 3-4, 25%) Pyrexia (grade 3-4, 25%) Pulmonary embolism (grade 3-4, 17%) Other AEs: Hypotension (grade 3-4, 17%) Sepsis (grade 3-4, 8%) Fatigue (all grades, 27%) Diarrhea (11%) Nausea (8%) Dysgeusia (11%) Weight loss (3%) Vomiting (11%) Anorexia (3%) Blood creatinine increased (8%) Dehydration (5%) Anemia (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021991lbl.pdf https://pubmed.ncbi.nlm.nih.gov/16960145

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467 inducer 707 supressor 19	inhibitor 1604 inducer 355	inhibitor 1702	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 98 P-gp 1330 CYP1A2 1383 CYP2B6 717 CYP2C8 818 CYP2C19 1325	CYP 236 P-gp 1400 UGT1A1 393 UGT1A3 397 UGT1A7 221 UGT1A8 266 UGT1A9 357 UGT2B7 362 UGT2B17 203	CYP1A2 637 CYP2B6 501 CYP2C19 269

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1514	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4, 6, 27	inconclusive	no (co-administration study) Comment: vorinostat has no inhibitory effect on the tranport of vinblastine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4, 6, 27
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 79.8 uM]
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP2B6 884	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP2C8 865	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP2C9 1648	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP3A4 1772	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6, 25, 26	no [IC50 >100 uM]
CYP 132	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021991s009lbl.pdf Page: 9.0	no
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 25.0	yes
CYP2B6 884	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 26.0	yes
CYP2C19 1392	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 26.0	yes
CYP2C9 1648	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 26.0	yes
CYP3A4 1772	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 26.0	yes
CYP3A4 1772	supressor 140 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_PharmR.pdf Page: 37.0	yes

Drug as victim

Target	Modality	Activity
P-gp 1400	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4, 6, 27	inconclusive
CYP 236	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 6.0	no
UGT1A1 393	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 3.0	yes
UGT1A3 397	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 3.0	yes
UGT1A7 221	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 3.0	yes
UGT1A8 266	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 3.0	yes
UGT1A9 357	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4.0	yes
UGT2B17 203	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4.0	yes
UGT2B7 362	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_ClinPharmR.pdf Page: 4.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinza_PharmR.pdf Page: 31.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45716	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45716
ChemicalBook	CB3506806	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3506806
MolPort	MolPort-003-850-293	https://www.molport.com/shop/molecule-link/MolPort-003-850-293
Selleck Chemicals	Vorinostat-(SAHA)	http://www.selleckchem.com/products/Vorinostat-(SAHA).html
ZINC	ZINC000001543873	http://zinc15.docking.org/substances/ZINC000001543873
eMolecules	1989084	https://www.emolecules.com/cgi-bin/more?vid=1989084

PubMed

Title	Date	PubMed
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.	2001	11250759
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.	2001 Dec 1	11731433
Phosphorus-based SAHA analogues as histone deacetylase inhibitors.	2003 Aug 21	12916979
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.	2003 Dec	14707268
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.	2003 Mar 1	12393499
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.	2003 May 1	12727828
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors.	2003 May 1	12594812
Histone deacetylase inhibitors up-regulate the expression of tight junction proteins.	2004 Dec	15634758
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.	2004 Feb 9	14741273
Gateways to clinical trials.	2004 Jun	15319815
[Therapeutic targets in polyglutamine diseases].	2004 May	15168543
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).	2004 May	15020838
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.	2004 May 15	15108350
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.	2004 Nov	15514602
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.	2004 Oct	15235103
High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum.	2005	15945019
Histone deacetylase inhibitors in programmed cell death and cancer therapy.	2005 Apr	15738652
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.	2005 Aug	16153448
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis.	2005 Aug	16133866
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.	2005 Aug 1	16061681
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.	2005 Dec	16123169
Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.	2005 Jan 17	15603949
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.	2005 Jul	15964800
Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines.	2005 Jul	15930892
Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.	2005 Jul 1	15927839
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.	2005 Jul 28	16033284
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.	2005 Jun	15754201
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.	2005 Jun 10	15897550
4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp.	2005 Mar	15787459
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.	2005 Mar	15744585
[Histone deacetylase inhibitors as a new generation of anti-cancer agents].	2005 Mar 11	15928589
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.	2005 Mar 15	15781658
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.	2005 May	15857402
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.	2005 May 15	15897598
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.	2005 Nov	16297208
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.	2005 Nov 1	16266998
Crystal structure of a bacterial class 2 histone deacetylase homologue.	2005 Nov 18	16242151
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.	2005 Sep	16197607
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.	2005 Sep	16015388
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.	2005 Sep 1	16144943
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.	2005 Sep 1	16140952
Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2.	2005 Sep 23	15994313
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.	2006 Apr 6	16314839
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.	2006 Jan	16343270
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.	2006 Jan	16328054
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.	2006 Jan 1	16330674
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.	2006 Jul 1	16450389
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.	2006 Mar	16465382
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.	2006 Mar 3	16377638
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.	2006 May 15	16434199

Patents

Sample Use Guides

In Vivo Use Guide

400 mg orally once daily with food. If patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.

Route of Administration: Oral

In Vitro Use Guide

Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 22:11:30 UTC 2021` Edited by `admin` on `Fri Jun 25 22:11:30 UTC 2021`
Record UNII	58IFB293JI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VORINOSTAT

Official Name

English

VORINOSTAT [MI]

Common Name

English

NSC-759852

Code

English

VORINOSTAT [ORANGE BOOK]

Common Name

English

NSC-701852

Code

English

N-HYDROXY-N'-PHENYLOCTANEDIAMIDE

Systematic Name

English

NSC-748799

Code

English

ZOLINZA

Brand Name

English

VORINOSTAT [WHO-DD]

Common Name

English

MK0683

Code

English

VORINOSTAT [MART.]

Common Name

English

MK-0683

Code

English

VORINOSTAT [USAN]

Common Name

English

OCTANEDIAMIDE, N-HYDROXY-N'-PHENYL-

Systematic Name

English

VORINOSTAT [INN]

Common Name

English

SUBEROYLANILIDE HYDROXAMIC ACID

Common Name

English

VORINOSTAT [JAN]

Common Name

English

VORINOSTAT [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

177203